Bedel Financial Consulting, Inc. Scynexis Inc Transaction History
Bedel Financial Consulting, Inc.
- $645 Million
- Q1 2024
Shares
3 transactions
Others Institutions Holding SCYX
# of Institutions
57Shares Held
15.4MCall Options Held
0Put Options Held
12.9K-
Federated Hermes, Inc. Pittsburgh, PA4.21MShares$8.22 Million0.01% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$4.36 Million0.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$3.29 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.45MShares$2.83 Million0.08% of portfolio
-
Amh Equity LTD660KShares$1.29 Million1.0% of portfolio
About SCYNEXIS INC
- Ticker SCYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 32,651,800
- Market Cap $63.7M
- Description
- SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...